The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Open accessAbstract
IMPORTANCE: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTIVE: To determine features associated with discontinuation of ibrutinib therapy and outcomes. DESIGN, SETTING, AND PARTICIPANTS: A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014. MAIN OUTCOMES AND MEASURES: Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse. RESULTS: With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-"not reached") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient. CONCLUSIONS AND RELEVANCE: This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not. TRIAL REGISTRATIONS: clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In published studies of disease progression during BTKi therapy,approximately 35% of patients were found to have aBTK mutation alone, an additional 10% had a coexisting mutations in PLCG2, 5% of cases had a PLCG2mutation alone, and the remaining 50% were wild-type (WT) for BTK and PLCG2 (Figure 2)(12, 19, 21–31).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, two separate studies observed that there were no PLCγ2 or BTK mutations detected in patients with CLL before Ibrutinib treatment (127, 128).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [128]
In the citing paper
“While the most common ibrutinib-resistant BTK mutant is C481S, other mutants observed in patients include C481R, C481F, C481Y, T474I, and T474S.33”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Ep, C., Chanana, A. D., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,789
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,725
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,665
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Self-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Cited by
Sorted by citations
Items 401–500 of 585
Quinquenel, A., de Fontbrune, F. S., Durot, É., Pannetier, M., Michonneau, D., Socié, G., Delmer, A. J., & de Latour, R. P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14029 · Cited by 7
Ibrutinib-resistant CLL: unwanted and unwonted!
Mertens, D., & Stilgenbauer, S. (2017) · Blood · doi:10.1182/blood-2017-01-761536 · Cited by 7
Targeting deubiquitinases in CLL.
Sampath, D. (2017) · Blood · doi:10.1182/blood-2017-06-786236 · Cited by 6
Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy
Gruessner, C., Wiestner, A., & Sun, C. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2466101 · Cited by 6
Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targets
Leo, I. R., Kunold, E., Audrey, A., Tampere, M., Eirich, J., Lehtiö, J., & Jafari, R. (2025) · Nature Communications · doi:10.1038/s41467-024-54654-8 · Cited by 6
Serrano-Sterling, C., Iriepa, I., Macias, M. A., Castillo, J., & Becerra, D. (2026) · RSC Advances · doi:10.1039/d5ra07121f · Cited by 6
The clinical safety of ibrutinib in chronic lymphocytic leukemia
Molica, S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1084286 · Cited by 6
Alsouqi, A., & Woyach, J. A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.019 · Cited by 6
Self-citationBenjamini, O., Fried, S., Shouval, R., Flynn, J. R., Beyar‐Katz, O., Leslie, L. A., Zucherman, T., Yerushalmi, R., Shem‐Tov, N., Palomba, M. L., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284664 · Cited by 6
Self-citationTargeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs
Vojnits, K., Feng, Z., Johnson, P. M., Porras, D. P., Manocha, E., Vandersluis, S., Pfammatter, S., Thibault, P., & Bhatia, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217108 · Cited by 6
Anagnostopoulos, I., Lakić, T., Balagué, O., van den Brand, M., Dirnhofer, S., Gašljević, G., Laurent, C., Ponzoni, M., Quintanilla‐Martínez, L., Sander, B., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04197-0 · Cited by 6
Molica, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1313108 · Cited by 6
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
Reda, G., Mattiello, V., Frustaci, A. M., Visentin, A., Mauro, F. R., Innocenti, I., Gentile, M., Giannarelli, D., Noto, A., Cassin, R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007619 · Cited by 6
Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective
Owen, C., Assouline, S. E., Kuruvilla, J. G., Uchida, C. L., Bellingham, C. M., & Sehn, L. H. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.649 · Cited by 6
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors
Qiu, H., Liu‐Bujalski, L., Caldwell, R. D., Follis, A. V., Gardberg, A. S., Goutopoulos, A., Grenningloh, R., Head, J. C., Johnson, T. L., Jones, C. C., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.018 · Cited by 6
LC-FACSeq is a method for detecting rare clones in leukemia
Hu, E. Y., Blachly, J. S., Saygin, C., Özer, H. G., Workman, S. E., Lozanski, A., Doong, T.-J., Chiang, C., Bhat, S. A., Rogers, K. A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134973 · Cited by 6
Self-citationCho, H. J., Baek, D. W., Kim, J., Lee, J. M., Moon, J. H., & Sohn, S. K. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1967139 · Cited by 6
Integrating New Therapies for Chronic Lymphocytic Leukemia
Burger, J. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000530 · Cited by 6
Recent advances in chronic lymphocytic leukemia therapy
Uhm, J. (2020) · Blood Research · doi:10.5045/br.2020.s012 · Cited by 6
Lin, Z.-C., Chan, M., Jaing, T., Lin, T., Hung, Y., & Su, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178747 · Cited by 7
Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia
Giudice, I. D., Starza, I. D., Falco, F. D., Gaïdano, G., & Sportoletti, P. (2024) · Cancers · doi:10.3390/cancers16112049 · Cited by 5
Wang, Y., Zhang, Y., Liu, J., Jiang, Y., Li, J., & Shi, W. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06515-7 · Cited by 5
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis
Nadiminti, K. V. G., Ahn, K. W., Patel, J., Lian, Q., Bezerra, E. D., Chen, A., Ganguly, S., Gergis, U. S., Hashmi, H., Kharfan‐Dabaja, M. A., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.07.021 · Cited by 5
Ayed, A. O., & Parikh, S. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1397665 · Cited by 5
Hess, B. T., Kalmuk, J., Znoyko, I. Y., Schandl, C. A., Wagner‐Johnston, N. D., Mazzoni, S. A., Hendrickson, L., Chiad, Z., Greenwell, I. B., & Wolff, D. J. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.10.003 · Cited by 5
Feng, S., Xiong, Y. H., Liu, W., Liu, H., Sui, W., Zheng, P., Meiling, S., Hu, K., & Zhang, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104551 · Cited by 5
Hussaini, M., Rehman, A., Chávez, J. C., Pinilla-Ibarz, J. A., & Horna, P. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1256482 · Cited by 5
Rola wenetoklaksu w leczeniu chorych na przewlekłą białaczkę limfocytową
Puła, B., & Jamroziak, K. (2017) · Hematologia · doi:10.5603/hem.2017.0003 · Cited by 5
Khountham, S., Shindiapina, P., Mo, X. M., Lachowiez, C. A., Wiczer, T. E., Mousa, L., Rogers, K. A., Andritsos, L. A., Woyach, J. A., Byrd, J. C., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1838508 · Cited by 5
Self-citationWu, Z., Wang, L., Fan, L., Tang, H., Zuo, X., Gu, D., Lü, X., Li, Y., Wu, J., Qin, S., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13281 · Cited by 5
Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
Jackson, R. A., Smith, V. M., Jayne, S., Drewes, C., Bens, S., Siebert, R., Dyer, M. J. S., & Walter, H. S. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000752 · Cited by 5
Godet, S., Protin, C. A., Dupuis, J., Dartigeas, C., Bastie, J., Herbaux, C., Leblond, V., de Guibert, S., Ghez, D., Brion, A., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24981 · Cited by 5
Aslan, B., Manyam, G. C., Iles, L. R., Tantawy, S. I., Desikan, S. P., Wierda, W. G., & Gandhi, V. V. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012360 · Cited by 4
Dong, X., Tang, S., Chen, M., Chen, Q., Wang, Y., Shi, Y., Deng, Y., Chen, Y., He, Z., Yu, L., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06775-x · Cited by 4
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
Tantawy, S. I., Aslan, B., Manyam, G. C., Iles, L. R., Timofeeva, N., Singh, N., Jain, N., Ferrajoli, A., Thompson, P. A., Patel, K. P., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01382-x · Cited by 4
Next-Generation Bruton Tyrosine Kinase Inhibitors
Stephens, D. M., & Byrd, J. C. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01594 · Cited by 4
Self-citationWhat is Fitness in the Era of Targeted Agents?
Tedeschi, A. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30472-9 · Cited by 4
Lu, X., Émond, B., Qureshi, Z. P., Wu, L. H., Forbes, S. P., Hilts, A., Liu, S., Lafeuille, M., Lefèbvre, P., Huang, Q., et al. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2243815 · Cited by 4
Passengers, drivers, and “goners”
Bunz, F. (2024) · International Journal of Cancer · doi:10.1002/ijc.35112 · Cited by 4
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia
Hatashima, A., & Shadman, M. S. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2391097 · Cited by 4
A rare manifestation of chronic lymphocytic leukaemia – leukaemia cutis treated with ibrutinib
Osmola, M., Gierej, B., Waszczuk‐Gajda, A., Kłosowicz, A., Hałaburda-Rola, M., Wiktor-Jędrzejczak, W., Basak, G. W., & Ziarkiewicz‐Wróblewska, B. (2019) · Medycyna Paliatywna · doi:10.5114/pm.2019.93186 · Cited by 4
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia
Gianfelici, V., Levato, L., & Molica, S. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00586-1 · Cited by 4
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients
Miller, C. R., Huang, Y., Ruppert, A. S., Labanowska, J. M., Jaglowski, S. M., Maddocks, K. J., Rogers, K. A., Bhat, S. A., Kittai, A. S., Grever, M. R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01237-x · Cited by 4
Self-citationA Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
Öztürk, E., & Özünal, I. E. (2021) · Medeniyet Medical Journal · doi:10.5222/mmj.2021.56424 · Cited by 4
Rjh, S., & Zain, R. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14204 · Cited by 4
Resistance to Bruton Tyrosine Kinase Inhibitors
Brown, J. R. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.05.009 · Cited by 4
Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors
Zhang, Y. S., Fu, H., Kang, X., Qiu, Z., Yan, H., He, Q., Yang, B., Xu, Z., & Luo, P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1726458 · Cited by 3
Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies
Yang, S., Oh, J., Hwang, S.-Y., Paik, J., & Hwang, I. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101383 · Cited by 3
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?
Frustaci, A. M., Deodato, M., Zamprogna, G., Cairoli, R., Montillo, M., & Tedeschi, A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.009 · Cited by 3
Updates on the Treatment of Richter’s Syndrome, Including Novel Combination Approaches
Jain, T., & Heyman, B. M. (2025) · Cancers · doi:10.3390/cancers17060943 · Cited by 3
Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver
Rogers, K. A., & Byrd, J. C. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.010 · Cited by 3
Self-citationEuropean Medicines Agency (EMA): Regulatory Perspectives on Geriatric Medicines
Cerreta, F., & Bowen, D. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-43099-7_34 · Cited by 3
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly
Ruella, M., & Soubeyran, P. (2016) · Hematology · doi:10.1182/asheducation-2016.1.432 · Cited by 3
Pálfi, T. G., Fésüs, V., Bödör, C., & Borbényi, Z. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30870 · Cited by 3
Venetoclax for the treatment of mantle cell lymphoma
Lin, V. S., Anderson, M. A., Huang, D. C. S., Roberts, A. W., Seymour, J. F., & Tam, C. S. L. (2019) · Annals of Lymphoma · doi:10.21037/aol.2019.03.02 · Cited by 3
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024) · eLife · doi:10.7554/elife.95488.3 · Cited by 3
Mamidi, M. K., Sinha, S., Mendez, M. T., Sanyal, T., Mahmud, H., Kay, N. E., Gupta, M., Xu, C., Vesely, S. K., Mukherjee, P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1192 · Cited by 3
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors
Garcia, M., Croizier, C., Lazarian, G., Quinquenel, A., Tassin, T., Bourgne, C., Tournilhac, O., Bay, J., Berger, M. G., Tchirkov, A., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06200-9 · Cited by 3
Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?
Noreña, I., Fernández‐Ruiz, M., & Aguado, J. M. (2020) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2020.10.019 · Cited by 3
Dimou, M., Bitsani, A., Roumelioti, M., Dimitrakopoulou, A., Iliakis, T., Pardalis, V., Grafakos, I., Kalyva, S., Markopoulos, A., Kyrtsonis, M., et al. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4002 · Cited by 3
Sigmund, A. M., Huang, Y., Ruppert, A. S., Maddocks, K. J., Rogers, K. A., Jaglowski, S. M., Bhat, S. A., Kittai, A. S., Grever, M. R., Byrd, J. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01640-y · Cited by 3
Self-citationChan, K. L., Lokan, J., Tam, C. S. L., Lew, T. E., & Prince, H. M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1179298 · Cited by 3
Genomics of Resistance to Targeted Therapies
Thangavadivel, S., & Woyach, J. A. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.03.004 · Cited by 3
Self-citationGenetics of Chronic Lymphocytic Leukemia
Bosch, F., & Dalla‐Favera, R. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000538 · Cited by 3
Fakhri, B., & Danilov, A. V. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.009 · Cited by 3
Miller, C. R., & Heerema, N. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8876-1_3 · Cited by 3
Self-citationProton radioactivity studies at the FMA
Penttilä, H., Davids, C. N., & Woods, P. J. (1995) · University of North Texas Digital Library (University of North Texas) · Cited by 3
Tang, P. S., & Tam, C. S. L. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1616189 · Cited by 3
Hematopoietic Cell Transplantation
Bashir, Q., Shpall, E. J., & Champlin, R. E. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm071.pub2 · Cited by 3
Zanubrutinib for the treatment of chronic lymphocytic leukemia
Bruzzese, A., Martino, E. A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2229734 · Cited by 3
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Kagerer, A., & Thompson, M. C. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.05.008 · Cited by 2
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi
Pak, M., Saurty-Seerunghen, M. S., Wise, K., Abera, T., Lama, C., Parghi, N., Kang, T., Sun, X., Gao, Q., Bao, L., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101036 · Cited by 2
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
Benrashid, S., & Woyach, J. A. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00776-3 · Cited by 3
Self-citationRationnel et modalités de prescription de l’ibrutinib dans les hémopathies lymphoïdes B
Dougé, A., Ravinet, A., Bay, J., Tournilhac, O., Guièze, R., & Lemal, R. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.12.003 · Cited by 2
Using genomic data for selecting the treatment of lymphoma patients
Batlevi, C. L., Shah, G. L., Forlenza, C. J., & Intlekofer, A. M. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000520 · Cited by 2
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity
Qiu, H., Ali, Z., Bowlan, J., Caldwell, R. D., Gardberg, A. S., Glaser, N., Goutopoulos, A., Head, J. C., Johnson, T. L., Maurer, C. K., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100453 · Cited by 2
Afonso, C., Gomes, M., Pereira, M. I., Faria, C., Pina, R., Saraiva, T., Geraldes, C., & Carda, J. P. (2022) · Clinical Case Reports · doi:10.1002/ccr3.6136 · Cited by 2
Zahra, K., Noura, B. Y., Wafa, C., Nesrine, B. S., Dorra, C., Walid, B., Zaier, M., Yosra, B. Y., Regaieg, H., & Abderrahim, K. (2023) · Health · doi:10.4236/health.2023.158056 · Cited by 2
Rigolin, G. M., Olimpieri, P. P., Summa, V., Celant, S., Scarfò, L., Ballardini, M. P., Urso, A., Gambara, S., Cavazzini, F., Ghia, P., et al. (2024) · HemaSphere · doi:10.1002/hem3.70017 · Cited by 2
Hafer, R., Iadevaia, F., Rohan, T. Z., Duong, T., Poluch, M. L., Keiffer, G., Li, M., Ferbér, A., Laurenti, L., Khoo, A. S. B., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100064 · Cited by 2
Frustaci, A. M., Montillo, M., Picardi, P., Mazzucchelli, M., Cairoli, R., & Tedeschi, A. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1191943 · Cited by 2
The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia
Jacobs, R. W., Awan, F. T., Leslie, L. A., Usmani, S. Z., & Ghosh, N. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1254545 · Cited by 2
Self-citationPharmacotherapy of relapsed/refractory chronic lymphocytic leukemia
Zahr, A. A., Bose, P., & Keating, M. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1324420 · Cited by 2
Resistance to Anti-Cancer Therapeutics
Woyach, J. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-23637-3_5 · Cited by 2
Self-citationThe Ongoing Unmet Needs in Chronic Lymphocytic Leukemia
Ding, W. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.04.001 · Cited by 3
Balakrishnan, K., Bojja, K., Decker, W. K., & Keating, M. J. (2017) · European Medical Journal · doi:10.33590/emj/10310971 · Cited by 2
Ibrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia
Frustaci, A. M., Tedeschi, A., Deodato, M., Mazzucchelli, M., Cairoli, R., & Montillo, M. (2017) · Future Oncology · doi:10.2217/fon-2017-0466 · Cited by 2
Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia
Robak, T. (2019) · Hematologic malignancies · doi:10.1007/978-3-030-11392-6_8 · Cited by 2
Chronic Lymphocytic Leukemia: Rapidly Changing Treatment Landscape
Samhouri, Y., Shah, R., & Khan, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88070 · Cited by 2
Changing landscape of frontline therapy in chronic lymphocytic leukemia
Bhat, S. A., & Woyach, J. A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1688321 · Cited by 2
Self-citationRelapsed disease and aspects of undetectable MRD and treatment discontinuation
Eichhorst, B. F., Fürstenau, M., & Hallek, M. J. (2019) · Hematology · doi:10.1182/hematology.2019000070 · Cited by 2
Raghunathan, V. M., Fan, G., Kittai, A. S., Okada, C. Y., Danilov, A. V., & Spurgeon, S. E. F. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13538 · Cited by 2
Burke, J. M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.017 · Cited by 2
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
Edelmann, J., Malčíková, J., & Riches, J. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1106579 · Cited by 3
Byrd, J. C., Smith, S. D., Wagner‐Johnston, N. D., Sharman, J. P., Chen, A. I., Advani, R. H., Augustson, B. M., Marlton, P. V., Commerford, S. R., Okrah, K., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27011 · Cited by 2
Self-citationNigris, E. D., Yang, X., Zanardo, E., Lejeune, D., Farooqui, M. Z. H., Gandra, S. R., & Laliberté, F. (2024) · Future Oncology · doi:10.1080/14796694.2024.2390351 · Cited by 1
JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL
Saleem, S. K., Decker, S., Kissel, S., Bauer, M., Chernyakov, D., Bräuer-Hartmann, D., Aumann, K., Wickenhauser, C., Herling, M., Skorobohatko, O., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230681 · Cited by 1
Nishikori, M., Nozaki, K., Hayashi, Y., Arita, Y., Fujiwara, M., Iwao, C., Kitagawa, H., & Maruyama, D. (2025) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.24049 · Cited by 1
Pfister, V., Marques, F. D. M., da Silveira, T. M. B., Filho, J. S., de Molla, V. C., Gonçalves, M. V., Yamamoto, M., Santucci, R., Aranha, M. A. F., de Farias, D. L. C., et al. (2025) · Blood Global Hematology · doi:10.1016/j.bglo.2025.100019 · Cited by 1
Rogers, K. A., Yan, P. S., Flinn, I. W., Stephens, D. M., Kipps, T. J., Larson, S. M., Martz, L., Chen, X., Wang, H., Hopping, E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0210 · Cited by 1
Self-citation
Metadata
- Authors
- Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., Mantel, R., Jones, J. A., Flynn, J. M., Jaglowski, S. M., Andritsos, L. A., Awan, F., Blum, K. A., Grever, M. R., Johnson, A. J., Byrd, J. C., & Woyach, J. A.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Woyach, Jennifer A.
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-04-01
- Volume
- 1
- Issue
- 1
- Pages
- 80
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC4520535
- OpenAlex
- W1999128869
- Cited by
- 584
- References
- 21
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 47 · 2021: 59 · 2020: 65 · 2019: 72 · 2018: 60 · 2017: 85 · 2016: 64 · 2015: 16
- FWCI
- 41.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, U10CA180861, P50CA140158, R01CA183444, P01CA95426, K23CA178183, R01CA177292, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- chronic lymphocytic leukemia, BTK inhibitors, treatment discontinuation, Richter transformation, BTK mutations, PLCG2 mutations, relapse, deep sequencing, prognostic factors, sequential clinical trials, targeted therapy resistance
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Mutation, Ohio, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Risk Factors, Time Factors, Biomarkers, Tumor, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Phospholipase C gamma, Kaplan-Meier Estimate, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
